Your Cart Is Empty!
How will breast cancer be treated in the years ahead - and what targeted therapies represent the greatest potential in terms of transforming disease therapy?
KOL Insight: Breast Cancer provides a comprehensive qualitative review of marketed and pipeline therapies in the breast cancer market with an emphasis on current and future treatment pathways. Interviews with 12 Key Opinion Leaders from the US and Europe add future-facing perspective and insights to the data.
This report includes key insights on the characterisation of optimal sequencing for HER2-positive breast cancer and how this might change, as well as the potential for new therapies for HER2-negative/HR-positive breast cancer and triple-negative breast cancer which may alter the treatment paradigm. The introduction of new CDK inhibitors, as well as the potential approval of PARP inhibitors in the future, are set to change the way the disease is treated.
- Better understand how your product is perceived, or likely to be perceived, by the marketplace
- Learn about the strengths and weaknesses of your competitors
- Understand different approaches to positioning that will put your product in the most favorable light possible
- Understand where the opportunities and threats are in the marketplace
- Gain insights required to better direct your sales and/or marketing teams toward success
Answers to Critical Questions
- Which drug is the treatment of choice for each patient segment, and what product attributes shape preference?
- Which clinical trials have the greatest potential to impact prescribing trends?
- How will the use of each product evolve in the future in terms of line of therapy and preference?
- How will the treatment landscape evolve in the future for each patient segment and line of therapy?
- What are the experts greatest concerns about new and future therapies?
Pipeline Therapies Covered
- AbbVie veliparib (ABT 888)
- AstraZeneca olaparib (Lynparza)
- BioMarin Pharmaceutical talazoparib (BMN 673)
- Boehringer Ingelheim Gilotrif (afatinib)
- Eli Lilly abemaciclib (LY 2835219)
- Galena Biopharma NeuVax (nelipepimut-S)
- Merck & Co./Tesaro niraparib (MK 4827)
- Novartis/Astex ribociclib (LEE 011)
- Novartis buparlisib (BKM 120)
- Puma Biotechnology neratinib
- Roche/Genentech taselisib (GDC 0032)
- Syndax Pharmaceuticals entinostat (SNDX 275)
Marketed Drugs Covered
- Genentech/Roche/Chugai Herceptin (trastuzumab)
- Genentech/Roche/Chugai Kadcyla (ado-trastuzumab emtansine)
- Genentech/Roche/Chugai Perjeta (pertuzumab)
- GlaxoSmithKline/Nippon Kayaku Tykerb (lapatanib)
- Novartis Afinitor (everolimus)
- Pfizer Ibrance (palbociclib)
- Comprehensive commercial and clinical profiles of each targeted therapy currently in market
- Summaries and analyses of all significant clinical trials now underway
- Overviews of current treatment algorithms based on patient segment, line of therapy, and patient characteristics
- The opinions and insights of a dozen KOLs, split equally between the US and Europe
- Summaries and analyses of current and future treatment pathways
Key Opinion Leaders
- Dr. Adam M. Brufsky, MD, PhD, Professor of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA
- Dr. Richard Finn, MD, Assistant Professor of Medicine, Geffen School of Medicine at UCLA, Department of Medicine, Division of Hematology/Oncology, Los Angeles, CA
- Dr. Reshma Mahtani, DO, Assistant Professor of Clinical Medicine, Division of Hematology/Oncology, Miller School of Medicine, University of Miami, Miami, FL
- Dr. Erica L. Mayer, MD MPH, Senior Physician, Susan F. Smith Center for Womens Cancers at the Dana-Farber Cancer Institute, Boston, MA; Assistant Professor in Medicine, Harvard Medical School, Boston, MA
- Dr. Joyce OShaughnessy, MD, Co-Chair of Breast Cancer Research, Baylor-Charles A. Sammons Cancer Center, Dallas, TX
- Dr. Charles Vogel, MD, Professor of Clinical Medicine, Division of Hematology/Oncology, Miller School of Medicine, University of Miami, Miami, FL
- Dr. Thomas Bachelot, MD, Head, Breast Cancer Unit and the Clinical Trial Unit, Centre Leon Berard, Lyon, France
- Dr. Adrian L. Harris, MD, DPhil, Professor of Medical Oncology, University of Oxford; Director, Cancer Research UK Medical Oncology Unit
- Dr. Chris Twelves, Professor of Clinical Cancer Pharmacology and Oncology and Head of Section of Oncology and Clinical Research, Leeds Cancer Research UK Centre, Leeds, UK
- Dr. Etienne GC Brain, MD PhD, Medical Oncologist, HOpital RenE Huguenin, Saint-Cloud, France
- Dr. VEronique DiEras, MD, Head, Department of Clinical Research and Chief of the Clinical Investigational Unit, Institut Curie, Paris, France and Saint Cloud, France
- Dr. Rafael Trujillo Vilchez, Medical Oncologist, Xanit International Hospital, Malaga, Spain
Update Bulletins Offer Ongoing Benefits
The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWords guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.
- Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the reports publication date, May 2015.
- You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.
Following are different modes of Licenses.
a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.
b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.
c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.
1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :
a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]
b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]
2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:
a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.